10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Clearbridge Investments LLC

Clearbridge Investments LLC trimmed its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Rating) by 24.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 424,704 shares of the company’s stock after selling 136,738 shares during the quarter. Clearbridge Investments LLC owned about 0.37% of 10x Genomics worth $15,476,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in TXG. BlackRock Inc. increased its position in 10x Genomics by 14.2% in the 1st quarter. BlackRock Inc. now owns 9,156,992 shares of the company’s stock valued at $696,572,000 after acquiring an additional 1,138,358 shares during the period. Baillie Gifford & Co. increased its position in 10x Genomics by 1.9% in the 4th quarter. Baillie Gifford & Co. now owns 8,602,235 shares of the company’s stock valued at $313,465,000 after acquiring an additional 158,847 shares during the period. Vanguard Group Inc. increased its position in 10x Genomics by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 8,274,359 shares of the company’s stock valued at $235,654,000 after acquiring an additional 446,601 shares during the period. Price T Rowe Associates Inc. MD increased its position in 10x Genomics by 75.5% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 2,349,229 shares of the company’s stock valued at $66,907,000 after acquiring an additional 1,010,643 shares during the period. Finally, Credit Suisse AG increased its position in 10x Genomics by 27.8% in the 3rd quarter. Credit Suisse AG now owns 2,154,964 shares of the company’s stock valued at $61,374,000 after acquiring an additional 468,207 shares during the period. 74.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other 10x Genomics news, CFO Justin J. Mcanear sold 1,665 shares of the firm’s stock in a transaction dated Tuesday, May 23rd. The stock was sold at an average price of $55.06, for a total transaction of $91,674.90. Following the transaction, the chief financial officer now directly owns 100,462 shares in the company, valued at $5,531,437.72. The transaction was disclosed in a filing with the SEC, which is available through this link. In other 10x Genomics news, insider Benjamin J. Hindson sold 2,388 shares of the firm’s stock in a transaction dated Tuesday, May 23rd. The stock was sold at an average price of $55.06, for a total transaction of $131,483.28. Following the transaction, the insider now directly owns 284,236 shares in the company, valued at $15,650,034.16. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Justin J. Mcanear sold 1,665 shares of the firm’s stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $55.06, for a total value of $91,674.90. Following the transaction, the chief financial officer now owns 100,462 shares in the company, valued at $5,531,437.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 43,655 shares of company stock worth $2,323,824. Corporate insiders own 11.08% of the company’s stock.

10x Genomics Stock Performance

TXG opened at $51.24 on Friday. 10x Genomics, Inc. has a 12-month low of $23.81 and a 12-month high of $58.30. The stock has a fifty day moving average of $52.58 and a 200-day moving average of $45.41.

10x Genomics (NASDAQ:TXG – Get Rating) last announced its quarterly earnings data on Wednesday, May 3rd. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.06). 10x Genomics had a negative return on equity of 22.02% and a negative net margin of 32.51%. The firm had revenue of $134.29 million for the quarter, compared to analysts’ expectations of $128.87 million. During the same quarter in the prior year, the business posted ($0.38) earnings per share. 10x Genomics’s revenue was up 17.3% on a year-over-year basis. On average, sell-side analysts anticipate that 10x Genomics, Inc. will post -1.39 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TXG has been the subject of a number of research reports. Canaccord Genuity Group increased their price target on 10x Genomics from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, February 16th. Stifel Nicolaus increased their price target on 10x Genomics from $57.00 to $68.00 in a research note on Thursday, May 4th. Cowen raised their price objective on 10x Genomics from $52.00 to $57.00 and gave the stock an “outperform” rating in a research note on Thursday, February 16th. Stephens started coverage on 10x Genomics in a research note on Thursday, March 30th. They set an “overweight” rating and a $65.00 price objective for the company. Finally, Morgan Stanley raised their price objective on 10x Genomics from $64.00 to $65.00 and gave the stock an “overweight” rating in a research note on Thursday, February 16th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $54.85.

10x Genomics Company Profile

(Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.